Literature DB >> 34987189

Contrasting results with second-line CAR T cells in large B cell lymphoma.

Diana Romero1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34987189     DOI: 10.1038/s41571-021-00598-7

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.

Authors:  Michael R Bishop; Michael Dickinson; Duncan Purtill; Pere Barba; Armando Santoro; Nada Hamad; Koji Kato; Anna Sureda; Richard Greil; Catherine Thieblemont; Franck Morschhauser; Martin Janz; Ian Flinn; Werner Rabitsch; Yok-Lam Kwong; Marie J Kersten; Monique C Minnema; Harald Holte; Esther H L Chan; Joaquin Martinez-Lopez; Antonia M S Müller; Richard T Maziarz; Joseph P McGuirk; Emmanuel Bachy; Steven Le Gouill; Martin Dreyling; Hideo Harigae; David Bond; Charalambos Andreadis; Peter McSweeney; Mohamed Kharfan-Dabaja; Simon Newsome; Evgeny Degtyarev; Rakesh Awasthi; Christopher Del Corral; Giovanna Andreola; Aisha Masood; Stephen J Schuster; Ulrich Jäger; Peter Borchmann; Jason R Westin
Journal:  N Engl J Med       Date:  2021-12-14       Impact factor: 91.245

2.  Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

Authors:  Frederick L Locke; David B Miklos; Caron A Jacobson; Miguel-Angel Perales; Marie-José Kersten; Olalekan O Oluwole; Armin Ghobadi; Aaron P Rapoport; Joseph McGuirk; John M Pagel; Javier Muñoz; Umar Farooq; Tom van Meerten; Patrick M Reagan; Anna Sureda; Ian W Flinn; Peter Vandenberghe; Kevin W Song; Michael Dickinson; Monique C Minnema; Peter A Riedell; Lori A Leslie; Sridhar Chaganti; Yin Yang; Simone Filosto; Jina Shah; Marco Schupp; Christina To; Paul Cheng; Leo I Gordon; Jason R Westin
Journal:  N Engl J Med       Date:  2021-12-11       Impact factor: 91.245

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.